In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Health Catalyst Inc (NASDAQ: HCAT) closed the day trading at $5.76 down -2.37% from the previous closing price of $5.90. In other words, the price has decreased by -$2.37 from its previous closing price. On the day, 1.53 million shares were traded. HCAT stock price reached its highest trading level at $6.105 during the session, while it also had its lowest trading level at $5.67.
Ratios:
For a better understanding of HCAT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.41 and its Current Ratio is at 1.41. In the meantime, Its Debt-to-Equity ratio is 1.03 whereas as Long-Term Debt/Eq ratio is at 0.37.
Evercore ISI Upgraded its In-line to Outperform on January 03, 2024, while the target price for the stock was maintained at $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 15 ’25 when LINDA LLEWELYN bought 6,442 shares for $5.90 per share.
LeSueur Daniel sold 5,209 shares of HCAT for $39,134 on Jan 06 ’25. The Chief Operating Officer now owns 91,253 shares after completing the transaction at $7.51 per share. On Jan 06 ’25, another insider, Landry Benjamin, who serves as the General Counsel of the company, sold 2,500 shares for $7.52 each. As a result, the insider received 18,796 and left with 72,250 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 350482752 and an Enterprise Value of 327558496. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.16 while its Price-to-Book (P/B) ratio in mrq is 0.99. Its current Enterprise Value per Revenue stands at 1.084 whereas that against EBITDA is -10.21.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.38, which has changed by -0.39979655 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $11.06, while it has fallen to a 52-week low of $5.42. The 50-Day Moving Average of the stock is -25.28%, while the 200-Day Moving Average is calculated to be -19.89%.
Shares Statistics:
Over the past 3-months, HCAT traded about 559.67K shares per day on average, while over the past 10 days, HCAT traded about 602940 shares per day. A total of 60.85M shares are outstanding, with a floating share count of 58.53M. Insiders hold about 3.81% of the company’s shares, while institutions hold 87.45% stake in the company. Shares short for HCAT as of 1735603200 were 2643994 with a Short Ratio of 4.72, compared to 1732838400 on 2554314. Therefore, it implies a Short% of Shares Outstanding of 2643994 and a Short% of Float of 4.4299997.
Earnings Estimates
Its stock is currently analyzed by 11.0 different market analysts. The consensus estimate for the next quarter is $0.1, with high estimates of $0.15 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.39 and $0.25 for the fiscal current year, implying an average EPS of $0.32. EPS for the following year is $0.42, with 14.0 analysts recommending between $0.66 and $0.18.
Revenue Estimates
14 analysts predict $80.57M in revenue for the current quarter. It ranges from a high estimate of $82M to a low estimate of $78.51M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $75.08MFor the next quarter, 14 analysts are estimating revenue of $83.06M. There is a high estimate of $84.66M for the next quarter, whereas the lowest estimate is $82.19M.
A total of 14 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $309M, while the lowest revenue estimate was $305.49M, resulting in an average revenue estimate of $307.55M. In the same quarter a year ago, actual revenue was $295.94MBased on 14 analysts’ estimates, the company’s revenue will be $341.67M in the next fiscal year. The high estimate is $346.64M and the low estimate is $337.2M.
